Get the Stockscreener App
28.09
4.85%
1.30
After Hours:
28.00
-0.09
-0.32%
Castle Biosciences Inc stock is traded at $28.09, with a volume of 1.56M.
It is up +4.85% in the last 24 hours and up +17.78% over the past month.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
See More
Previous Close:
$26.79
Open:
$28.75
24h Volume:
1.56M
Relative Volume:
4.04
Market Cap:
$851.97M
Revenue:
$339.92M
Net Income/Loss:
$-12.83M
P/E Ratio:
-65.40
EPS:
-0.4295
Net Cash Flow:
$4.52M
1W Performance:
+13.79%
1M Performance:
+17.78%
6M Performance:
-28.69%
1Y Performance:
+85.41%
1-Day Range:
$27.50
$30.81
1-Week Range:
$23.73
$30.81
52-Week Range:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Name
Castle Biosciences Inc
Sector
Industry
Phone
866-788-9007
Address
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
28.09 | 741.26M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
574.38 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
195.02 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.07 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
IQV
Iqvia Holdings Inc
|
235.07 | 35.59B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
138.37 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Apr-30-21 | Initiated | Lake Street | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-27-19 | Reiterated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | BTIG Research | Buy |
| Aug-19-19 | Initiated | Canaccord Genuity | Buy |
| Aug-19-19 | Initiated | Robert W. Baird | Outperform |
| Aug-19-19 | Initiated | SVB Leerink | Outperform |
View All
Castle Biosciences Inc Stock (CSTL) Latest News
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Cash Flow - TradingKey
Earnings Preview: CSTL to Report Financial Results Post-market on July 30 - Moomoo
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences, Inc. (CSTL) Investor Outlook: Exploring A 67.89% Potential Upside - DirectorsTalk Interviews
CSTL|Castle Biosciences Inc|Price:25.093|Chg%:-0.387 - TradingKey
Castle Biosciences sets live webcast for Aug. 12 conference - Stock Titan
New York State Department of Health Approves Castle’s AdvanceAD-Tx Test - The Dermatology Digest
The Technical Signals Behind (CSTL) That Institutions Follow - Stock Traders Daily
Castle Biosciences CEO Maetzold sells $95,622 in company stock - Investing.com UK
Form 4 Castle Biosciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Castle Biosciences CEO Maetzold sells $95,622 in company stock By Investing.com - Investing.com UK
Castle Biosciences (CSTL) CEO sells 4,172 shares via family trusts - Stock Titan
Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - Bitget
Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test - Moomoo
Castle Biosciences receives New York approval for atopic dermatitis test By Investing.com - Investing.com Nigeria
Castle Biosciences receives New York approval for atopic dermatitis test - Investing.com
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test - norfolkneradio.com
CSTL Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Uncertain Revenue Outlook - DonanımHaber
Castle Biosciences Inc (CSTL) Stock Down 3.4% -- Now Undervalued? GF Score: 77/100 - GuruFocus
CSTL Q1 2026 Earnings: Slight EPS Beat Amid Operational ProgressRevenue Guidance Update - DonanımHaber
July 30 set for Castle Biosciences Q2 2026 earnings webcast - Traders Union
Castle Biosciences (CSTL) to Release Q2 Financial Results on Jul - GuruFocus
Castle Biosciences sets July 30 webcast for Q2 results - Stock Titan
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 - Yahoo Finance
Castle Biosciences updates its melanoma testing strategy as diagnostics demand grows - Ad-hoc-news.de
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - AOL.com
Castle Biosciences (CSTL) COO sells 8,586 shares under 10b5-1 plan - Stock Titan
Form 4 Castle Biosciences Inc For: 6 July By Investing.com - Investing.com Nigeria
Derek Maetzold, pres. & CEO, sells $238,916 of Castle Biosciences stock - Investing.com India
Castle Biosciences (CSTL) CEO sells 9,836 shares via 10b5-1 plan - Stock Titan
Q1 2026 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Enterprise value to revenue forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Castle Biosciences Inc (CSTL) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Form 144 Castle Biosciences For: 1 July By Investing.com - Investing.com Canada
Maetzold family Rule 144 sales reported for CSTL (CSTL) — multiple small lots - Stock Titan
Castle Biosciences (CSTL) Surges 6% as Bullish Momentum BuildsDynamic Hedging - dars.gov.et
Castle Biosciences updates its melanoma test data, shares in biotech focus - AD HOC NEWS
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool By Investing.com - Investing.com South Africa
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - norfolkneradio.com
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
Castle Biosciences Inc Stock (CSTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Castle Biosciences Inc Stock (CSTL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 14 '26 |
Sale |
22.92 |
3,622 |
83,016 |
12,090 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 14 '26 |
Sale |
22.92 |
550 |
12,606 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Option Exercise |
2.39 |
6,214 |
14,851 |
27,693 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Sale |
24.29 |
6,214 |
150,938 |
21,479 |
| MAETZOLD DEREK J | Pres. & Chief Exec. Officer |
Jul 01 '26 |
Sale |
24.29 |
3,622 |
87,978 |
12,368 |
| Oelschlager Kristen M | Chief Operating Officer |
Jul 01 '26 |
Sale |
24.42 |
8,586 |
209,650 |
21,874 |
0.55%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):